The European Centre for Disease Prevention and Control warned Monkeypox could become endemic if the outbreak continues. The ECDC said that, if person-to-person transmission continues, it could become entrenched on the continent. (STAT News)
The Food and Drug Administration lifted its clinical hold on Ocugen’s COVID-19 vaccine trial. The FDA paused the trials of the shot, Covaxin,after a World Health Organization inspection of a Bharat Biotech facility revealed deficiencies in the manufacturing process. (Reuters)
Moderna has debuted on the Fortune 500 list. The COVID-19 vaccine manufacturer joined pharma mainstays such as Johnson & Johnson, Pfizer and AbbVie. (Fortune)
Rapid reinfection changed the COVID-19 fight, according to a New Republic commentary. “With a virus that spreads year-round, is capable of reinfection, is still evolving rapidly and with few public protections still in place, we could be facing a future where we all get sick several times a year,” wrote Melody Schreiber. (The New Republic)
Concert Pharmaceuticals’ stock remains on a hot streak. On Monday, Concert reported positive topline results for its oral investigational medicine CTP-543 in adult patients with moderate to severe alopecia areata. (InvestorsObserver)
